The enzyme LDHB, which was found to be upregulated in the LB- subtype, may help identify breast cancers most likely to respond to neoadjuvant chemotherapy as well as those with the highest risk of relapse that may benefit from additional adjuvant therapy [61]. This evidence concerns the gene LDHB and breast carcinoma.